Drug evaluation based on phosphomimetic PDHA1 reveals the complexity of activity-related cell death in A549 non-small cell lung cancer cells = Drug evaluation based on phosphomimetic PDHA1 reveals the complexity of activity-related cell death in A549 non-small cell lung cancer cells

다국어 초록 (Multilingual Abstract)

Cancer cells predominantly generate energy via glycolysis, even in the presence of oxygen, to support abnormal cell proliferation. Suppression of PDHA1 by PDK1 prevents the conversion of cytoplasmic pyruvate into Acetyl-CoA. Several PDK inhibitors have been identified, but their clinical applications have not been successful for unclear reasons. In this study, endogenous PDHA1 in A549 cells was silenced by the CRISPR/Cas9 system, and PDHA1^WT and PDHA1^3SD were transduced. Since PDHA1^3SD cannot be phosphorylated by PDKs, it was used to evaluate the specific activity of PDK inhibitors. This study highlights that PDHA1^WT and PDHA1^3SD A549 cells can be used as a cell-based PDK inhibitor-distinction system to examine the relationship between PDH activity and cell death by established PDK inhibitors. Leelamine, huzhangoside A and otobaphenol induced PDH activity-dependent apoptosis, whereas AZD7545, VER-246608 and DCA effectively enhanced PDHA1 activity but little toxic to cancer cells. Furthermore, the activity of phosphomimetic PDHA1 revealed the complexity of its regulation, which requires further in-depth investigation. [BMB Reports 2021; 54(11): 563-568]

참고문헌 (Reference)

1 Gatenby RA, "Why do cancers have high aerobic glycolysis?" 4 : 891-899, 2004

2 Moore JD, "VER-246608, a novel pan-isoform ATP competitive inhibitor of pyruvate dehydrogenase kinase, disrupts Warburg metabolism and induces context-dependent cytostasis in cancer cells" 5 : 12862-, 2014

3 Vander Heiden MG, "Understanding the Warburg effect : the metabolic require ments of cell proliferation" 324 : 1029-1033, 2009

4 Hitosugi T, "Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolism" 44 : 864-877, 2011

5 Kroemer G, "Tumor cell metabolism : Cancer’s Achilles’ heel" 13 : 472-482, 2008

6 Stacpoole PW, "Therapeutic targeting of the pyruvate dehydrogenase complex/pyruvate dehydrogenase kinase(PDC/PDK)axis in cancer" 109 : 11-, 2017

7 Kato M, "Structural basis for inactivation of the human pyruvate dehydrogenase complex by phosphorylation : role of disordered phosphorylation loops" 16 : 1849-1859, 2008

8 Guerra-Castellano A, "Structural and functional characterization of phosphomimetic mutants of cytochrome c at threonine 28 and serine 47" 1857 : 387-395, 2016

9 Korotchkina LG, "Site specificity of four pyruvate dehydrogenase kinase isoenzymes toward the three phosphorylation sites of human pyruvate dehydrogenase" 276 : 37223-37229, 2001

10 Jing E, "Sirt3 regulates metabolic flexibility of skeletal muscle through reversible enzymatic deacetylation" 62 : 3404-3417, 2013

11 정남호, "Role of Pyruvate Dehydrogenase Kinase 4 in Regulation of Blood Glucose Levels" 대한당뇨병학회 34 (34): 274-283, 2010

12 Kolobova E, "Regulation of pyruvate dehydrogenase activity through phosphorylation at multiple sites" 358 : 69-77, 2001

13 Wang X, "Pyruvate dehydrogenase kinases(PDKs) : an overview toward clinical applications" 41 : BSR2020440-, 2021

14 McFate T, "Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cells" 283 : 22700-22708, 2008

15 정남호, "Pyruvate Dehydrogenase Kinases: Therapeutic Targets for Diabetes and Cancers" 대한당뇨병학회 39 (39): 188-197, 2015

16 Li J, "Pivotal role of the C-terminal DW-motif in mediating inhibition of pyruvate dehydrogenase kinase 2 by dichloroacetate" 284 : 34458-34467, 2009

17 Zimmer AD, "Phosphorylation of the pyruvate dehydrogenase complex precedes HIF-1-mediated effects and pyruvate dehydrogenase kinase 1 upregulation during the first hours of hypoxic treatment in hepatocellular carcinoma cells" 4 : 135-, 2016

18 Cai Z, "Phosphorylation of PDHA by AMPK drives TCA cycle to promote cancer metastasis" 80 : 263-278, 2020

19 Liu T, "PDK1 promotes tumor cell proliferation and migration by enhancing the Warburg effect in non-small cell lung cancer" 37 : 193-200, 2017

20 Korotchkina LG, "Mutagenesis studies of the phosphorylation sites of recombinant human pyruvate dehydrogenase. Site-specific regulation" 270 : 14297-14304, 1995

21 Sun W, "JX06 selectively inhibits pyruvate dehydrogenase kinase PDK1 by a covalent cysteine modification" 75 : 4923-4936, 2015

22 Sun W, "JX06 selectively inhibits pyruvate dehydrogenase kinase PDK1 by a covalent cysteine modification" 75 : 4923-4936, 2015

23 Sradhanjali S, "Inhibition of pyruvate dehydrogenase kinase as a therapeutic strategy against cancer" 18 : 444-453, 2018

24 Kwak CH, "Ilimaquinone induces the apoptotic cell death of cancer cells by reducing pyruvate dehydrogenase kinase 1 activity" 21 : 6021-, 2020

25 Golias T, "Hypoxic repression of pyruvate dehydrogenase activity is necessary for metabolic reprogramming and growth of model tumours" 6 : 1-11, 2016

26 Kwak CH, "Huzhangoside A suppresses tumor growth through inhibition of pyruvate dehydrogenase kinase activity" 11 : 712-, 2019

27 Jin L, "Hemistepsin A suppresses colorectal cancer growth through inhibiting pyruvate dehydrogenase kinase activity" 10 : 1-12, 2020

28 Pelicano H, "Glycolysis inhibition for anticancer treatment" 25 : 4633-, 2006

29 Zheng J, "Energy metabolism of cancer : glycolysis versus oxidative phosphorylation" 4 : 1151-1157, 2012

30 Kato M, "Distinct structural mechanisms for inhibition of pyruvate dehydrogenase kinase isoforms by AZD7545, dichloroacetate, and radicicol" 15 : 992-1004, 2007

31 SALE GJ, "Analysis of site occupancies in [32P] phosphorylated pyruvate dehydrogenase complexes by aspartyl‐prolyl cleavage of tryptic phosphopeptides" 120 : 535-540, 1981

32 Mayers R, "AZD7545, a novel inhibitor of pyruvate dehydrogenase kinase 2(PDHK2), activates pyruvate dehydrogenase in vivo and improves blood glucose control in obese(fa/fa)Zucker rats" 31 : 1165-1167, 2003

33 Schell JC, "A role for the mitochondrial pyruvate carrier as a repressor of the Warburg effect and colon cancer cell growth" 56 : 400-413, 2014